<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04079452</url>
  </required_header>
  <id_info>
    <org_study_id>DORACeNeS</org_study_id>
    <secondary_id>2018-003915-24</secondary_id>
    <nct_id>NCT04079452</nct_id>
  </id_info>
  <brief_title>Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals</brief_title>
  <official_title>Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacio Lluita Contra la SIDA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut d'Investigació Biomèdica de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacio Lluita Contra la SIDA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Doravirine is a new HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) that has
      demonstrated a good efficacy and safety profile in clinical trials. It functions by
      inhibiting viral replication of both wild-type virus and most common NNRTI variants. It is
      dosed orally once daily and always given in combination with other HIV-1 active agents as
      part of highly active antiretroviral therapy. Initial pharmacokinetic studies demonstrated
      not extensive binding to plasma proteins, which may be crucial determinant for penetration to
      different reservoirs such as the central nervous system (CNS). This study will address two
      important issues: The pharmacokinetic profile of Doravirine in cerebrospinal fluid (CSF) as
      well as the maintenance of HIV suppression in CSF. The assessment of concentrations as well
      as the antiviral activity of new antiretroviral drugs in compartments such as CNS is relevant
      to avoid HIV-related neurocognitive disorders as well as for future cure strategies. In
      addition, the role of unbound ARV drug concentrations has been scarcely evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      15 asymptomatic, virologically suppressed, HIV infected patients will be offered to switch
      their antiretroviral treatment to Doravirine+Emtricitabine/TAF. After 4 weeks of treatment
      all subjects will undergo lumbar puncture and bloods in order to assess CSF and plasma (total
      and unbound) Doravirine concentrations. HIV RNA also will be assessed. All subjects will
      complete a follow up visit 4 weeks after
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Doravirine concentrations in CSF</measure>
    <time_frame>4 Weeks</time_frame>
    <description>To determine total and unbound Doravirine concentrations in cerebrospinal fluid in HIV-1 infected individual receiving ART with Doravirine+FTC/TAF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Doravirine concentrations in blood plasma</measure>
    <time_frame>4 Weeks</time_frame>
    <description>Total Doravirine concentrations in blood plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Doravirine CSF/plasma ratio</measure>
    <time_frame>4 Weeks</time_frame>
    <description>Doravirine CSF/plasma ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV-1 RNA in cerebrospinal fluid</measure>
    <time_frame>4 Weeks</time_frame>
    <description>HIV-1 RNA in cerebrospinal fluid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV-1 RNA in blood plasma</measure>
    <time_frame>4 Weeks</time_frame>
    <description>HIV-1 RNA in blood plasma</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Doravirine + Descovy® TAF/FTC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doravirine (MK-1439) 100 mg administered orally once daily in combination with Tenofovir alafenamide (TAF) and emtricitabine (FTC) coformulated as single tablet (Descovy® TAF/FTC 25/200 mg) and administered orally once daily during 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doravirine</intervention_name>
    <description>Doravirine 100 mg tablet</description>
    <arm_group_label>Doravirine + Descovy® TAF/FTC</arm_group_label>
    <other_name>MK-1439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Descovy</intervention_name>
    <description>Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet</description>
    <arm_group_label>Doravirine + Descovy® TAF/FTC</arm_group_label>
    <other_name>TAF/FTC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Asymptomatic, HIV-1 infected individuals ≥ 18 years of age

          2. Be on a stable ART continously or ≥3 consecutive months preceding the screening visit.
             Patients already receiving TAF/FTC+DoravirineC for at least three consecutive months
             will be eligible.

          3. Plasma HIV-1 RNA at screening &lt;40 copies/mL for at least 3 months at the Screening
             visit.

          4. Signed and dated written informed consent prior to inclusion.

          5. Subjects must agree to utilize a highly effective method of contraception during
             heterosexual intercourse from the screening visit throughout the duration of the
             study.

        Exclusion Criteria:

          1. Severe hepatic impairment (Child-Pugh Class C)

          2. Ongoing malignancy

          3. Active opportunistic infection

          4. Primary resistance to any of the ARV included in the study or history of virologic
             failure with risk of resistance selection to any of the study drugs.

          5. Any verified Grade 4 laboratory abnormality

          6. ALT or AST ≥ 3xULN and/or bilirubin ≥ 1.5xULN

          7. Adequate renal function: Estimated glomerular filtration rate ≥ 50 mL/min

          8. Females who are pregnant (as confirmed by positive serum pregnancy test) or
             breastfeeding.

          9. Current treatment with antiaggregant or anticoagulant therapy.

         10. History of any neurologic disease/condition/treatment may alter the blood brain
             barrier permeability.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Podzamczer, PhD Chief</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan Manuel Tiraboschi, PhD</last_name>
    <phone>+34932607667</phone>
    <phone_ext>2885</phone_ext>
    <email>jmtiraboschi@bellvitgehospital.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arkaitz Imaz, PhD</last_name>
    <phone>+34932607667</phone>
    <phone_ext>2883</phone_ext>
    <email>aimaz@bellvitgehospital.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Camila Piatti</last_name>
      <phone>+34933359011</phone>
      <phone_ext>2876</phone_ext>
      <email>cpiatti@bellvitgehospital.cat</email>
    </contact>
    <contact_backup>
      <last_name>Laura Acerete</last_name>
      <phone>+34933359011</phone>
      <phone_ext>2876</phone_ext>
      <email>lacerete@bellvitgehospital.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Podzamczer, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Manuel Tiraboschi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arkaitz Imaz, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 3, 2019</study_first_submitted>
  <study_first_submitted_qc>September 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacio Lluita Contra la SIDA</investigator_affiliation>
    <investigator_full_name>Daniel Podzamczer</investigator_full_name>
    <investigator_title>PhD: chief of the HIV and STD Unit (Infectious Disease Service)</investigator_title>
  </responsible_party>
  <keyword>Doravirine</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

